Literature DB >> 15329031

A decision chart for assessing and improving the transferability of economic evaluation results between countries.

Robert Welte1, Talitha Feenstra, Hans Jager, Reiner Leidl.   

Abstract

OBJECTIVE: To develop a user-friendly tool for managing the transfer of economic evaluation results.
METHODS: Factors that may influence the transfer of health economic study results were systematically identified and the way they impact on transferability was investigated. A transferability decision chart was developed that includes: knock-out criteria; a checklist based on the transferability factors; and methods for improving transferability and for assessing the uncertainty of transferred results. This approach was tested on various international cost-effectiveness studies in the areas of interventional cardiology, vaccination and screening.
RESULTS: The transfer of study results is possible pending the outcomes of the transferability check and necessary adjustments. Transferability factors can be grouped into areas of methodological, healthcare system and population characteristics. Different levels of effort are required for analysis of factors, ranging from very low (e.g. discount rate) to very high (e.g. practice variation). The impact of differences of most transferability factors can be estimated via the key health economic determinants: capacity utilisation, effectiveness, productivity loss and returns to scale. Depending on the outcomes of the transferability check a correction of the study results for inflation and for differences related to currencies or purchasing power might be sufficient. Otherwise, modelling-based adjustments might be necessary, requiring the (re-)building and sometimes structural modification of the study model. For determination of the most essential adjustments, a univariate sensitivity analysis seems appropriate. If not all relevant study parameters can be substituted with country-specific ones, multivariate or probabilistic sensitivity analysis seems to be a promising way to quantify the uncertainty associated with a transfer. If study results cannot be transferred, the transfer of study models or designs should be investigated as this can significantly save time when conducting a new study.
CONCLUSIONS: Our transferability decision chart is a transparent and user-friendly tool for assessing and improving the transferability of economic evaluation results. A state of the art description of the methodology in a study, providing detailed components for calculation, is not only essential for determining its transferability but also for improving it via modelling adjustments.

Mesh:

Year:  2004        PMID: 15329031     DOI: 10.2165/00019053-200422130-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  79 in total

1.  [German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus. Hannover Consensus Group].

Authors: 
Journal:  Med Klin (Munich)       Date:  2000-01-15

Review 2.  Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.

Authors:  D A Revicki; L Frank
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

3.  Extrapolation of cost-effectiveness information to local settings.

Authors:  S Bryan; J Brown
Journal:  J Health Serv Res Policy       Date:  1998-04

Review 4.  Making cost assessments based on RCTs more useful to decision-makers.

Authors:  R Baltussen; A Ament; R Leidl
Journal:  Health Policy       Date:  1996-09       Impact factor: 2.980

5.  Estimating country-specific cost-effectiveness from multinational clinical trials.

Authors:  R J Willke; H A Glick; D Polsky; K Schulman
Journal:  Health Econ       Date:  1998-09       Impact factor: 3.046

6.  Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada.

Authors: 
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

7.  The relation between surgical volume and mortality: an exploration of causal factors and alternative models.

Authors:  H S Luft
Journal:  Med Care       Date:  1980-09       Impact factor: 2.983

8.  An international study of patient compliance with hemodialysis.

Authors:  A J Bleyer; B Hylander; H Sudo; Y Nomoto; E de la Torre; R A Chen; J M Burkart
Journal:  JAMA       Date:  1999-04-07       Impact factor: 56.272

9.  Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Economic evaluation of a phase III clinical trial in Europe and Australia.

Authors:  H Glick; R Willke; D Polsky; T Llana; W M Alves; N Kassell; K Schulman
Journal:  Int J Technol Assess Health Care       Date:  1998       Impact factor: 2.188

10.  Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery.

Authors:  D J Cohen; J A Breall; K K Ho; R M Weintraub; R E Kuntz; M C Weinstein; D S Baim
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

View more
  76 in total

1.  Transferability of economic evaluation results.

Authors:  Fernando Antoñanzas
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.

Authors:  Pearl D Gumbs; Monique W M Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  The impact of BMI on direct costs in children and adolescents: empirical findings for the German Healthcare System based on the KiGGS-study.

Authors:  Christina M Wenig
Journal:  Eur J Health Econ       Date:  2010-09-29

Review 4.  Challenges of translating genetic tests into clinical and public health practice.

Authors:  Wolf H Rogowski; Scott D Grosse; Muin J Khoury
Journal:  Nat Rev Genet       Date:  2009-07       Impact factor: 53.242

5.  The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations.

Authors:  Sinaa A Al Aqeel; Mohammed Al-Sultan
Journal:  Saudi Pharm J       Date:  2011-12-24       Impact factor: 4.330

6.  Methodological reviews of economic evaluations in health care: what do they target?

Authors:  Maria-Florencia Hutter; Roberto Rodríguez-Ibeas; Fernando Antonanzas
Journal:  Eur J Health Econ       Date:  2013-08-24

Review 7.  Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region.

Authors:  Federico Augustovski; Cynthia Iglesias; Andrea Manca; Michael Drummond; Adolfo Rubinstein; Sebastián García Martí
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 8.  International comparison of cost of falls in older adults living in the community: a systematic review.

Authors:  J C Davis; M C Robertson; M C Ashe; T Liu-Ambrose; K M Khan; C A Marra
Journal:  Osteoporos Int       Date:  2010-02-27       Impact factor: 4.507

Review 9.  Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.

Authors:  Cécile Gaujoux-Viala; Bruno Fautrel
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

10.  Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis.

Authors:  T Enden; S Resch; C White; H S Wik; N E Kløw; P M Sandset
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.